Available online at http://jddtonline.info

RESEARCH ARTICLE

SYNTHESIS, CHARACTERIZATION AND BILOGICAL SCREENING OF SOME NOVEL INDOLE BASED 1,2,4-TRIAZOLO 1,3,4-THIADIAZINES

Mahipal Reddy Yata, Raghu Vardhan Reddy Mekala*, Ravi Prasad Talagadadivi

Department of Chemistry, Kakatiya University, Warangal, Andhra Pradesh, India

*Corresponding Author's E mail: drmrvr@gmail.com

ABSTRACTS:

A series of novel 3-(1*H*-indole-4-yl)-6-aryl-7*H*-[1,2,4]-triazolo-[3,4-*b*][1,3,4]-thiadiazines (**6a-f**) were synthesized by involving 1*H*-indole-4-carboxylic acid (**1**) as raw material and 1*H*-indole-4-carboxylic acid ethyl ester (**2**), 1*H*-indole-4-carboxylic acid hydrazide (**3**), 5-(1*H*-indole-4-yl)-[1,3,4]oxadiazole-2-thiol (**4**) and 4-amino-5-(1*H*-indol-4-yl)-4*H*-[1,2,4]-triazole-3-thiol (**5**)as intermediates. The chemical structures of the all newly synthesized compounds were elucidated by their IR, ¹H and ¹³ C NMR, mass spectral data and elemental analysis. Further, the target compounds were used to find their antifungal and nematicidal activity.

Key-Words: Indole, 1,2,4-Triazole, 1,3,4-Thiadiazines, Antifungal activity, Nematicidal activity.

INTRODUCTION:

Recently, it was reported that the heterocyclic moiety such as triazole based thiadiazoles and thiadiazines possess variety of pharmacological activities like antimicrobial ¹ antiviral ² antibacterial, ³ antiinflammatory, ⁴ herbicidal ⁵ and anti-HIV-1.⁶ On the other hand, it has been reported that certain compounds bearing a thiadiazole and 1,2,4-triazole nucleus possess significant anti-inflammatory activity. ⁷

These initial reports stimulated us to integrate thiadiazine moiety in triazole frame work, since these systems possess well documented antimicrobial and nematicidal activity. The target compounds, 3-(1H-indole-4-yl)-6-aryl-7H-[1,2,4]-triazolo-[3,4-b][1,3,4]-thiadiazines (**6a-f**) have been prepared by using commercially available 1*H*-indole-4-carboxylic acid (**1**) as raw material and by involving 1*H*-indole-4-carboxylic acid ethyl ester (**2**), 1*H*-indole-4-carboxylic acid hydrazide (**3**), <math>5-(1H-indole-4-yl)-[1,3,4]oxadiazole-2-thiol (**4**) and 4-amino-5-(1H-indole-4-yl)-4H-[1,2,4]-triazole-3-thiol (**5**) as intermediates.

The initial intermediate, 1*H*-indole-4-carboxylic acid ethyl ester (2) has been prepared through esterification

by boiling of a mixture of 1H-indole-4-carboxylic acid (1) and sulfuric acid in ethanol for 4 h. The compound 2 was reacted with hydrazine hydrate in absolute ethyl alcohol at reflux for 8 h to get 1H-indole-4-carboxylic acid hydrazide (3). The intermediate, 5-(1H-indole-4-yl)-[1,3,4]oxadiazole-2-thiol (4) for the synthesis of title compounds was prepared by the cyclization of compound 3 with carbon disulphide in the presence of potassium hydroxide in ethanol at reflux for 14 h followed by acidification. Further the compound 4 when reacted with hydrazine hydrate in ethanol at reflux for 6 h resulted 4-amino-5-(1H-indol-4-yl)-4H-[1,2,4]triazole-3-thiol (5). Finally, the compound 5 has been condensed successively with a variety of phenacylbromides in ethyl alcohol under reflux for 8-10 h to get the title compounds, 3-(1H-indole-4-yl)-6-aryl-7H-[1,2,4]triazolo-[3,4-b][1,3,4]-thiadiazines (**6a-f**). The chemical structures of the all newly synthesized compounds were elucidated by their IR, ¹H and ¹³ C NMR, mass spectral data and elemental analysis. Further, the target compounds were used to find their antifungal and nematicidal activity.



Scheme 1: $6 \text{ Ar} = (a) C_6 H_5$; (b) 4-OCH₃C₆H₄; (c) 4-ClC₆H₄; (d) 4-BrC₆H₄; (e) 4-NO₂C₆H₄; (f) 4-OHC₆H₄; (e) 4-NO₂C₆H₄; (f) 4-OHC₆H₄; (

Journal of Drug Delivery & Therapeutics; 2014, 4(2), 43-46 Table 1: *In vitro* antifungal activity of compounds 6a-f (MIC in µg/mL)

Compound	C. albicans	A. Fumigatus	T. Rubrum	T. Mentropyhte	
6a	25.0	12.5	>50.0	25.0	
6b	25.0	25.0	25.0	25.0	
6с	12.5	6.25	3.12	3.12	
6d	25.0	12.5	6.25	12.5	
6e	3.12	12.5	12.5	25.0	
6f	50.0	25.0	12.5	12.5	
Amphotericin B	6.25	3.12	3.12	3.12	

Table 2: Median lethal dose (LD ₅₀ , ppm) of compo	ounds	6a-f	f
---	-------	------	---

Nematicide	6a	6b	6c	6d	6e	6f	Levamisole
D. myceliophagus	170	270	950	430	570	190	170
C. elegans	190	220	870	200	610	780	180

ANTIFUNGAL ACTIVITY

Compounds 6a-f were screened for their antifungal activity against four fungal organisms viz., Candida albicans, Aspergillus fumigatus, Trichophyton rubrum, and Trichophyton mentagrophytes in dimethyl sulfoxide by broth dilution method.^[8] The minimum inhibitory concentration (MIC, µg/mL) were measured and compared with the standard drug Aamphotericin B (Table 1). Among the screened compounds, 6c is highly active against T. rubrum, T. mentagrophytes, 6e is also active against only C. albicans and 6g is highly active against C. albicans, T. mentagrophytes and the activity of these compounds are almost equal to the standard. All the compounds in this series exhibited either excellent or moderate activity towards different organisms. None of the compounds is inactive against any one of the organism. It is interesting to note that 6e showed excellent antifungal activity towards C. albicans at the concentration of 3.12 µg/mL, which is less than the concentration of the standard.

NEMATICIDAL ACTIVITY

All the newly synthesized compounds **6 a-f** in this study were also assayed for their nematicidal activity against Ditylenchus myceliophagus and Caenorhabditis elegans by aqueous *in vitro* screening technique^[9] at various concentrations. The results have been expressed in terms of LD₅₀ *i.e.* median lethal dose at which 50% nematodes became immobile (dead), and compared with the standard drug levamisole. The screened data reveal that, **6a** is the most effective against *D. myceliophagus* and *C.* elegans with LD₅₀ of 170 and 190 ppm, respectively. The compounds **6d** and **6f** are also most active against C. elegans with LD_{50} of 200 ppm and D. myceliophagus with LD_{50} of 190 ppm, respectively. The activity of **6a** is almost equal to the activity of the standard Levamisole. The other tested compounds showed moderate activity. The LD₅₀ values of the compounds screened are presented in Table 2.

EXPERIMENTAL

© 2011, JDDT. All Rights Reserved JDDTAO

All the reagents and solvents were used as purchased without further purification. Melting points were determined on a Fisher–Johns melting point apparatus and are uncorrected. IR spectra were obtained on a Perkin-Elmer BX serried FTIR 5000 spectrometer using KBr pellet. NMR spectra were recorded on a Varian 300 MHz spectrometer for ¹H–NMR and 100 MHz for ¹³C–NMR. The chemical shifts were reported as ppm down field using TMS as an internal standard. Mass spectra were recorded on a VG-Micromass 7070H spectrometer operating at 70 eV.

1H-Indole-4-carboxylic acid ethyl ester (2) To the solution of 1*H*-indole-4-carboxylic acid (1) (0.01 mol) in absolute ethyl alcohol (15 ml), conc. H_2SO_4 (2 ml) was added. The mixture was refluxed for 4 h. After completion of the reaction (monitored by TLC), the solvent was removed under reduced pressure and the obtained residue was recrystallized with petroleum ether to get pure 1*H*-indole-4-carboxylic acid ethyl ester (2).

1*H***-Indole-4-carboxylic acid hydrazide (3)** A mixture of 1*H*-indole-4-carboxylic acid ethyl ester (2) (0.01 mol) and hydrazine hydrate (0.025 mol) in ethanol (20 ml) was refluxed for 8 h. After completion of the reaction (monitored by TLC), the mixture was cooled to room temperature and filtered. The crude product was recrystallized from ethanol to give 1*H*-indole-4-carboxylic acid hydrazide (3) in pure form.

5-(1*H***-Indole-4-yl)-[1,3,4]oxadiazole-2-thiol (4)** A mixture of 1*H*-indole-4-carboxylic acid hydrazide (3) (0.01 mol), potassium hydroxide (0.02 mol) and carbon disulfide (0.03 mol) in ethanol (100 mL) was heated under reflux with stirring for 14 h. The solvent was distilled *in vacuo*, the residual mass was poured over crushed ice and neutralized the alkaline solution with 10% hydrochloric acid. The precipitated crude product was filtered, washed with water, dried and recrystallized from ethanol to get the pure compound 5-(1*H*-indole-4-yl)-[1,3,4]oxadiazole-2-thiol (4).

ISSN: 2250-1177

4-Amino-5-(1*H***-indol-4-yl)-4***H***-[1,2,4]-triazole-3-thiol (5) To a warm solution of 5-(1H-indole-4-yl)-[1,3,4]-oxadiazole-2-thiol (4) (0.01 mol) in ethanol (20 mL), 80% hydrazine hydrate (0.03 mol) was added drop wise and the reaction mixture was heated under reflux for 7 h. The solvent was distilled off** *in vacuo***, cooled and the solid separated were filtered, washed with cold ethanol and recrystallized from chloroform to give pure compound 4-amino-5-(1***H***-indol-4-yl)-4***H***-[1,2,4]-triazole-3-thiol (5).**

3-(1H-indole-4-yl)-6-aryl-7H-[1,2,4]-triazolo-[3,4-

b][1,3,4]-thiadiazines (6a-f) A mixture of 4-amino-5-(1*H*-indol-4-yl)-4*H*-[1,2,4]-triazole-3-thiol (5) (0.01 mol) and corresponding phenacylbromide (0.02 mol) in absolute ethanol (20 mL) was refluxed for 8–10 h. The reaction mixture was concentrated and cooled to room temperature, and the remaining solvent was removed under reduced pressure, then diethyl ether (25 mL) was added and the reaction mixture was left at 0 °C for overnight. The precipitated solid was filtered off. The crude product thus obtained was purified by column chromatography on silica gel with hexane-ethyl acetate as eluent to afford pure 3-(1*H*-indole-4-yl)-6-aryl-7*H*-[1,2,4]-triazolo-[3,4-*b*][1,3,4]-thiadiazines (**6a-f**).

PHYSICAL AND SPECTRAL DATA

1*H***-Indole-4-carboxylic acid ethyl ester (2)** Yellow solid; yield 78%; bp 342-343 °C; IR (KBr) cm⁻¹: 3212 (N-H), 3024 (Ar-H), 2962 (C-H, CH₃), 1699(C=N), 1588 (C=C); ¹H-NMR (CDCl₃) δ : 1.24 (3H, t, *J* = 5.6 Hz, CH₃), 4.00 (2H, q, *J* = 5.6 Hz, CH₂), 7.42 (1H, d, *J* = 7.4 Hz, Ar-H), 7.39-7.62 (3H, m, Ar-H), 7.85 (1H, d, *J* = 7.4 Hz, Ar-H), 11.12 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 13.6, 59.1, 106.3, 112.5, 119.4, 121.7, 122.8, 126.3, 130.4, 132.5, 165.4; MS *m*/*z*: 189 (M⁺); Elemental analysis calculated for C₁₁H₁₁NO₂: C-69.83, H-5.86, N-7.40, O-16.91. Found: C-67.36, H-5.42, N-7.06, O-15.98.

1*H***-Indole-4-carboxylic acid hydrazide (3)** Brown solid; yield 81%; mp 187-189 °C; IR (KBr) cm⁻¹: 3318 (NH₂), 3218 (N-H), 3065 (Ar-H), 1645 (C=N), 1548 (C=C); ¹H-NMR (CDCl₃) δ : 5.30 (2H, s, NH₂), 7.38 (1H, d, *J* = 7.2 Hz, Ar-H), 7.42-7.64 (3H, m, Ar-H), 7.70 (1H, s, NH), 7.79 (1H, d, *J* = 7.2 Hz, Ar-H), 11.06 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 105.7, 114.2, 121.0, 123.7, 124.4, 127.3, 132.7, 135.3, 162.3; MS *m*/*z*: 175 (M⁺); Elemental analysis calculated for C₉H₉N₃O: C-61.70, H-5.18, N-23.99, O-9.13. Found: C-60.12, H-4.89, N-22.17, O-8.89.

5-(1*H***-Indole-4-yl)-[1,3,4]oxadiazole-2-thiol (4)** Pale yellow solid; yield 74%; mp 185-187 °C; IR (KBr) cm⁻¹: 3236 (N-H), 3028 (Ar-H), 2610 (S-H), 1648 (C=N), 1559 (C=C), 1155; ¹H-NMR (CDCl₃) δ : 3.81 (1H, s, SH), 7.35 (1H, d, J = 7.6 Hz, Ar-H), 7.41-7.58 (3H, m, Ar-H), 7.79 (1H, d, J = 7.6 Hz, Ar-H), 11.24 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 102.4, 116.3, 120.7, 123.4, 125.8, 128.4, 136.1, 139.8, 145.6, 158.9; MS *m*/*z*: 217 (M⁺); Elemental analysis calculated for C₁₀H₇N₃OS: C-55.29, H-3.25, N-19.34, O-7.69, S-14.76. Found: C-53.69, H-3.12, N-18.45, O-7.02, S-13.38.

4-Amino-5-(1*H***-indol-4-yl)-4***H***-[1,2,4]-triazole-3-thiol (5) White solid; yield 72%; mp 147-149 °C; IR (KBr) © 2011, JDDT. All Rights Reserved JDDTAO** cm⁻¹: 3248 (N-H), 3018 (Ar-H), 2648 (S-H), 1662 (C=N), 1552 (C=C); ¹H-NMR (CDCl₃) δ : 3.65 (1H, s, SH), 3.85 (2H, s, NH₂), 7.37 (1H, d, J = 7.3 Hz, Ar-H), 7.45-7.74 (3H, m, Ar-H), 7.80 (1H, d, J = 7.3 Hz, Ar-H), 11.21 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 105.6, 110.8, 116.7, 119.4, 127.6, 129.4, 132.4, 137.6, 142.3, 152.7; MS m/z: 231 (M⁺); Elemental analysis calculated for C₁₀H₉N₅S: C-51.93, H-3.92, N-30.28, S-13.86. Found: C-50.12, H-3.45, N-29.65, S-12.98.

3-(1*H*-Indole-4-yl)-6-phenyl-7*H*-[1,2,4]-triazolo-[3,4-

b][1,3,4]-thiadiazine (6a) Pink solid; yield 75%; mp 158-160 °C; IR (KBr) cm⁻¹: 3245 (N-H), 3018 (Ar-H), 2965 (C-H, CH₂), 1638 (C=N), 1548 (C=C); ¹H-NMR (CDCl₃) δ : 1.86 (2H, s, CH₂), 7.32 (1H, d, J = 6.8 Hz, Ar-H), 7.41-7.74 (8H, m, Ar-H), 7.79 (1H, d, J = 6.8 Hz, Ar-H), 10.98 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 33.7, 104.3, 116.7, 121.0, 125.4, 126.3, 128.7 (2), 129.7, 130.2, 131.7 (2), 132.7, 133.1, 138.4, 144.2, 148.7, 162.3; MS *m*/*z*: 331 (M⁺); Elemental analysis calculated for C₁₈H₁₃N₅S: C-65.24, H-3.95, N-21.13, S-9.68. Found: C-63.25, H-3.64, N-20.28, S-8.95.

3-(1H-Indole-4-yl)-6-(4-methoxy-phenyl)-7H-[1,2,4]-

triazolo-[3,4-b][1,3,4]-thiadiazine (6b) Pink solid; yield 80%; mp 162-164 °C; IR (KBr) cm⁻¹: 3239 (N-H), 3024 (Ar-H), 2960 (C-H, CH₂), 1642 (C=N), 1568 (C=C), 1145 (C-O); ¹H-NMR (CDCl₃) δ : 1.74 (2H, s, CH₂), 1.24 (3H, s, CH₃), 7.29 (1H, d, *J* = 7.0 Hz, Ar-H), 7.32 (2H, d, *J* = 7.2 Hz, Ar-H), 7.40 (2H, d, *J* = 7.2 Hz, Ar-H), 7.42-7.81 (3H, m, Ar-H), 7.85 (1H, d, *J* = 7.0 Hz, Ar-H), 10.84 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 30.3, 44.7, 106.7, 118.4, 123.4, 126.3, 128.7, 129.6 (2), 130.7, 132.7, 133.2 (2), 134.1, 135.2, 137.4, 146.7, 149.5, 163.1; MS *m*/*z*: 361 (M⁺); Elemental analysis calculated for C₁₉H₁₅N₅OS: C-63.14, H-4.18, N-19.38, O-4.43, S-8.87. Found: C-61.23, H-3.84, N-18.28, O-4.12, S-7.84.

3-(1H-Indole-4-yl)-6-(4-chloro-phenyl)-7H-[1,2,4]-

triazolo-[3,4-*b***][1,3,4]-thiadiazine (6c)** Yellow solid; yield 82%; mp 126-128 °C; IR (KBr) cm⁻¹: 3240 (N-H), 3028 (Ar-H), 2958 (C-H, CH₂), 1654 (C=N), 1595 (C=C); ¹H-NMR (CDCl₃) δ : 1.68 (2H, s, CH₂), 7.26 (1H, d, *J* = 7.4 Hz, Ar-H), 7.30 (2H, d, *J* = 7.0 Hz, Ar-H), 7.38 (2H, d, *J* = 7.0 Hz, Ar-H), 7.46-7.76 (3H, m, Ar-H), 7.79 (1H, d, *J* = 7.4 Hz, Ar-H), 10.92 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 32.3, 104.2, 116.2, 119.7, 122.0, 124.2, 125.3 (2), 128.4, 136.3, 139.2 (2), 140.2, 141.0, 142.7, 148.7, 150.2, 165.7; MS *m*/*z*: 365 (M⁺); Elemental analysis calculated for C₁₈H₁₂ClN₅S: C-59.09, H-3.31, Cl-9.69, N-19.14, S-8.76. Found: C-57.16, H-3.14, Cl-8.84, N-18.56, S-7.48.

3-(1H-Indole-4-yl)-6-(4-bromo-phenyl)-7H-[1,2,4]-

triazolo-[3,4-*b***][1,3,4]-thiadiazine (6d)** Brown solid; yield 81%; mp 132-134 °C; IR (KBr) cm⁻¹: 3258 (N-H), 3032 (Ar-H), 2962 (C-H, CH₂), 1664 (C=N), 1565 (C=C); ¹H-NMR (CDCl₃) δ : 1.54 (2H, s, CH₂), 7.16 (1H, d, *J* = 7.3 Hz, Ar-H), 7.26 (2H, d, *J* = 7.3 Hz, Ar-H), 7.34 (2H, d, *J* = 7.5 Hz, Ar-H), 7.40-7.68 (3H, m, Ar-H), 7.72 (1H, d, *J* = 7.5 Hz, Ar-H), 10.86 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 36.3, 107.4, 112.0, 115.7, 118.6, 120.8, 122.3 (2), 124.7, 132.6, 134.8 (2), 138.7, 140.2, 145.7, 146.3, 152.7, 163.8; MS *m*/*z*: 410 (M⁺); Elemental analysis calculated for C₁₈H₁₂BrN₅S: C-52.69, H-2.95, Br-19.47,

ISSN: 2250-1177

Mekala et al

Journal of Drug Delivery & Therapeutics; 2014, 4(2), 43-46

N-17.07, S-7.89. Found: C-50.36, H-2.65, Br-18.84, N-16.47, S-9.89.

3-(1*H*-Indole-4-yl)-6-(4-nitro-phenyl)-7*H*-[1,2,4]-

triazolo-[3,4-b][1,3,4]-thiadiazine (6e) White solid; yield 79%; mp 154-156 °C; IR (KBr) cm⁻¹: 3262 (N-H), 3027 (Ar-H), 2945 (C-H, CH₂), 1652 (C=N), 1556 (C=C); ¹H-NMR (CDCl₃) δ : 1.58 (2H, s, CH₂), 7.26 (1H, d, *J* = 6.8 Hz, Ar-H), 7.31 (2H, d, *J* = 6.8 Hz, Ar-H), 7.38 (2H, d, *J* = 7.2 Hz, Ar-H), 7.45-7.72 (3H, m, Ar-H), 7.78 (1H, d, *J* = 7.2 Hz, Ar-H), 11.08 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 33.7, 108.9, 114.7, 117.4, 119.6, 122.3, 124.7 (2), 126.8, 133.7, 135.8 (2), 139.7, 142.4, 148.7, 149.6, 153.7, 164.9; MS *m*/*z*: 376 (M⁺); Elemental analysis calculated for C₁₈H₁₂N₆O₂S: C-57.44, H-3.21, N-22.33, O-8.50, S-8.52. Found: C-55.98, H-3.12, N-21.28, O-7.87, S-7.95.

3-(1*H***-Indole-4-yl)-6-(4-hydroxy-phenyl)-7***H***-[1,2,4]-triazolo-[3,4-b][1,3,4]-thiadiazine (6f)** Pale solid; yield 77%; mp 139-141 °C; IR (KBr) cm⁻¹: 3256 (N-H), 3042 (Ar-H), 2938 (C-H, CH₂), 1665 (C=N), 1548 (C=C); ¹H-NMR (CDCl₃) δ : 1.46 (2H, s, CH₂), 5.02 (1H, s, OH), 7.22 (1H, d, *J* = 7.0 Hz, Ar-H), 7.35 (2H, d, *J* = 7.0 Hz, Ar-H), 7.40 (2H, d, *J* = 7.4 Hz, Ar-H), 7.48-7.78 (3H, m, Ar-H), 7.84 (1H, d, *J* = 7.4 Hz, Ar-H), 11.10 (1H, s, NH); ¹³C-NMR (CDCl₃) δ : 30.3, 112.8, 115.4, 116.3, 121.4, 123.7, 126.8 (2), 128.7, 135.7, 138.7 (2), 140.2, 143.6, 145.7, 147.8, 151.6, 165.6; MS *m*/*z*: 347 (M⁺); Elemental analysis calculated for C₁₈H₁₃N₅OS: C-62.23, H-3.77, N-20.16, O-4.61, S-9.23. Found: C-60.54, H-3.42, N-19.65, O-4.21, S-8.85.

REFERENCES:

- 1) Demirbas N, Karaoglu SA, Demirbas A, Celik E, Arkivoc. 2005, (i), 75-91.
- Marina K, Anastasia M, Panagiotis M, Nicole P, Spyroula P-G, Christophe P, Myriam W, Erik De C, *Il Farmaco* 2002, 57, 253-257.
- Xiao-Wen S, Zhang Yan, Zhang Zi-Yi, Wang Qin, Wang Shu-Fang, Indian J Chem. 1999, 38B, 380-383.
- Udupi RH, Suresh GV, Setty SR, Bhat AR, *J Indian Chem Soc.* 2000, 77, 302-304.
- 5) Nizamuddin, Gupta M, Khan MH, Srivastava MK, J Sci Ind Res. **1999**, 58, 538-542.

6) Invidiata FP, Simoni D, Scintu F, Pinna N, Farmaco. 1996, 51, 659-664.

- Tozkoparan B, Gokhan N, Aktay G, Yesilada E, Ertan M, Eur J Med Chem. 2000, 35, 743-750.
- C.A. Winter, E.A. Risley, G.N. Nus Carrageenin-induced edema in hind paw of the rat as assay for antiinflammatory drugs, *Proc Soc Exp Biol Med.* 111, **1962**, 544.
- National Committee for Clinical Laboratory Standards (NCCLS). Standard methods for dilution antimicrobial susceptibility tests for bacteria, which grows aerobically. *Nat. Comm. Lab. Stands*, Villanova, **1982**, 242.